Zymeworks (ZYME) appointed Oleg Nodelman to its board of directors, effective February 17. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. Nodelman represents the seventh new director elected or appointed over the past two years as part of the company’s board renewal process. He currently serves as a director of two other publicly-traded life science companies, Galapagos NV and AnaptysBio.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks to Announce 2024 Financial Results and Host Corporate Update
- Zymeworks to Engage Investors at Key Conferences
- Zymeworks Sets Strategic Milestones for 2025-2026 with Focus on Novel Therapeutics
- Biotech Alert: Searches spiking for these stocks today
- Zymeworks price target raised to $14 from $12 at Wells Fargo